ReviewTranslational vision science & technology2026
Pathogenicity Analysis of Two Novel CRB1 Mutations in Three Chinese Inherited Retinal Dystrophy Families and a Literature Review.
Review in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to analyze the clinical features of three inherited retinal dystrophies (IRDs) pedigrees with CRB1 mutations, and assess pathogenicity of novel variants. Methods: A retrospective clinical study was conducted, involving three IRD pedigrees. Whole exome sequencing was performed. The in silico molecular genetic analysis and bioinformatics analysis were conducted. Western blot and cycloheximide chase experiments were used for protein expression and stability. We also conducted a literature review to analyze diagnosis and mutation distribution characteristics of reported Chinese patients with CRB1-IRD. Results: Three probands, including two cone-rod dystrophy (CORD) and one retinitis pigmentosa (RP), carried compound heterozygous CRB1 variants. Six variants were identified, including two novel variants (c.1122C>G: p.S374R and c.2233A>G: p.T745A). In vitro, the expression levels of CRB1 with S374R variant significantly reduced. The S374R, G1288S, and T745A showed accelerated protein degradation rates and reduced protein stability. Literature review revealed 3 high-frequency mutation regions and 13 high-frequency mutation sites in the Chinese CRB1-IRD population, with approximately 95% of patients diagnosed with Leber congenital amaurosis (LCA) or RP. Conclusions: This study identified two novel CRB1 mutations that reduced CRB1 expression by impairing protein stability. In literature review, we identified 3 mutation hotspots and 13 recurrent mutations in Chinese patients with CRB1-IRD. Translational Relevance: We identified two novel CRB1 variants impairing protein stability. Combined with mutation hotspots identified in Chinese patients, enhancing genetic screening accuracy and expanding ethnic-specific mutation databases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.